RU2014116196A - Crystal Anhydrous Delta Modification of N- (2-Chloro-6-Methylphenyl) -2 - [[6- [4- (2-Hydroxyethyl) -1-Piperazinyl] -2-Methyl-4-Pyrimidinyl] Amino] THIAZOLCARBOXAMIDE, METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION ON ITS BASIS - Google Patents

Crystal Anhydrous Delta Modification of N- (2-Chloro-6-Methylphenyl) -2 - [[6- [4- (2-Hydroxyethyl) -1-Piperazinyl] -2-Methyl-4-Pyrimidinyl] Amino] THIAZOLCARBOXAMIDE, METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION ON ITS BASIS Download PDF

Info

Publication number
RU2014116196A
RU2014116196A RU2014116196/04A RU2014116196A RU2014116196A RU 2014116196 A RU2014116196 A RU 2014116196A RU 2014116196/04 A RU2014116196/04 A RU 2014116196/04A RU 2014116196 A RU2014116196 A RU 2014116196A RU 2014116196 A RU2014116196 A RU 2014116196A
Authority
RU
Russia
Prior art keywords
piperazinyl
pyrimidinyl
methylphenyl
hydroxyethyl
chloro
Prior art date
Application number
RU2014116196/04A
Other languages
Russian (ru)
Other versions
RU2567537C1 (en
Inventor
Александр Александрович Малин
Олег Ростиславович Михайлов
Николай Александрович Уваров
Original Assignee
Олег Ростиславович Михайлов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54362649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2014116196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Олег Ростиславович Михайлов filed Critical Олег Ростиславович Михайлов
Priority to RU2014116196/04A priority Critical patent/RU2567537C1/en
Publication of RU2014116196A publication Critical patent/RU2014116196A/en
Application granted granted Critical
Publication of RU2567537C1 publication Critical patent/RU2567537C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1. Кристаллическая безводная δ-модификация N-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида, характеризующаяся следующим набором межплоскостных расстояний (d, Å) и соответствующих им интенсивностей (I, %): 9,637 - 69,1%; 7,928 - 29,2%; 6,415 - 100%; 5,819 - 39,4%; 5,529 - 3,0%; 4,941 - 27,2%; 4,887 - 5,6%; 4,549 - 72,6%; 4,092 - 3,8%; 4,037 - 3,2%; 3,847 - 35,0%; 3,782 - 5,8%; 3,751 - 5,2%; 3,642 - 3,9%; 3,607 - 2,7%; 3,442 - 16,6%; 3,383 - 3,0%; 3,183 - 27,4%; 3,122 - 21,7%; 3,099 - 5,6%; 2,958 - 6,9%; 2,905 - 3,4%; 2,763 - 7,5%; 2,757 - 7,8%; 2,694 - 9,2%; 2,551 - 12,6%; 2,516 - 2,6%; 2,463 - 3,9%; 2,292 - 3,9%; 2,270 - 5,0%; 2,137 - 4,0%; 2,112 - 3,5%; 2,024 - 3,7%; 1,906 - 3,4%; 1,867 - 3,0%; 1,780 - 6,0%.2. Способ получения кристаллической безводной δ-модификации N-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида по п. 1, характеризующейся тем, что растворяют N-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамид в органическом растворителе, выделяют кристаллиты из раствора методом замены растворителя или охлаждением с последующим фильтрованием, промыванием, замораживают кристаллиты и подвергают сублимационной сушке в течение 22-27 часов при конечной температуре на продукте не менее 25°C.3. Способ по п. 2, характеризующийся тем, что для промывания используют дистиллированную воду.4. Способ по п. 2 или 3, характеризующийся тем, что конечная температура при сублимационной сушке на продукте составляет 25°C-60°C.5. Применение кристаллической безводной δ-модификации N-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида по п. 1, обладающей ингибирующей активностью в отношении тирозинкиназ, для приготовления фармацевтической композиции для лечен�1. Crystalline anhydrous δ-modification of N- (2-chloro-6-methylphenyl) -2 - [[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl-4-pyrimidinyl] amino] - 5-thiazolecarboxamide, characterized by the following set of interplanar distances (d, Å) and their corresponding intensities (I,%): 9.637 - 69.1%; 7.928 - 29.2%; 6.415 - 100%; 5.819 - 39.4%; 5.529 - 3.0%; 4.941 - 27.2%; 4.887 - 5.6%; 4.549 - 72.6%; 4.092 - 3.8%; 4.037 - 3.2%; 3.847 - 35.0%; 3,782 - 5.8%; 3.751 - 5.2%; 3.642 - 3.9%; 3.607 - 2.7%; 3.442 - 16.6%; 3.383 - 3.0%; 3.183 - 27.4%; 3.122 - 21.7%; 3.099 - 5.6%; 2.958 - 6.9%; 2.905 - 3.4%; 2.763 - 7.5%; 2.777 - 7.8%; 2,694 - 9.2%; 2.551 - 12.6%; 2.516 - 2.6%; 2.463 - 3.9%; 2.292 - 3.9%; 2.270 - 5.0%; 2.137 - 4.0%; 2.112 - 3.5%; 2.024 - 3.7%; 1,906 - 3.4%; 1.867 - 3.0%; 1.780 - 6.0% .2. The method of obtaining crystalline anhydrous δ-modification of N- (2-chloro-6-methylphenyl) -2 - [[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl-4-pyrimidinyl] amino] - 5-thiazolecarboxamide according to claim 1, characterized in that N- (2-chloro-6-methylphenyl) -2 - [[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl-4 is dissolved -pyrimidinyl] amino] -5-thiazolecarboxamide in an organic solvent, crystallites are isolated from the solution by solvent replacement or cooling, followed by filtration, washing, crystallites are frozen and freeze-dried for 22-27 hours a final product temperature of at least 25 ° C.3. The method according to claim 2, characterized in that distilled water is used for washing. The method according to claim 2 or 3, characterized in that the final temperature during freeze-drying on the product is 25 ° C-60 ° C. 5. The use of crystalline anhydrous δ-modification of N- (2-chloro-6-methylphenyl) -2 - [[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl-4-pyrimidinyl] amino] -5 -thiazolecarboxamide according to claim 1, having tyrosine kinase inhibitory activity, for the preparation of a pharmaceutical composition for the treatment of

Claims (5)

1. Кристаллическая безводная δ-модификация N-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида, характеризующаяся следующим набором межплоскостных расстояний (d, Å) и соответствующих им интенсивностей (Iотн., %): 9,637 - 69,1%; 7,928 - 29,2%; 6,415 - 100%; 5,819 - 39,4%; 5,529 - 3,0%; 4,941 - 27,2%; 4,887 - 5,6%; 4,549 - 72,6%; 4,092 - 3,8%; 4,037 - 3,2%; 3,847 - 35,0%; 3,782 - 5,8%; 3,751 - 5,2%; 3,642 - 3,9%; 3,607 - 2,7%; 3,442 - 16,6%; 3,383 - 3,0%; 3,183 - 27,4%; 3,122 - 21,7%; 3,099 - 5,6%; 2,958 - 6,9%; 2,905 - 3,4%; 2,763 - 7,5%; 2,757 - 7,8%; 2,694 - 9,2%; 2,551 - 12,6%; 2,516 - 2,6%; 2,463 - 3,9%; 2,292 - 3,9%; 2,270 - 5,0%; 2,137 - 4,0%; 2,112 - 3,5%; 2,024 - 3,7%; 1,906 - 3,4%; 1,867 - 3,0%; 1,780 - 6,0%.1. Crystalline anhydrous δ-modification of N- (2-chloro-6-methylphenyl) -2 - [[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl-4-pyrimidinyl] amino] - 5-thiazolecarboxamide, characterized by the following set of interplanar distances (d, Å) and their corresponding intensities (I rel. ,%): 9.637 - 69.1%; 7.928 - 29.2%; 6.415 - 100%; 5.819 - 39.4%; 5.529 - 3.0%; 4.941 - 27.2%; 4.887 - 5.6%; 4.549 - 72.6%; 4.092 - 3.8%; 4.037 - 3.2%; 3.847 - 35.0%; 3,782 - 5.8%; 3.751 - 5.2%; 3.642 - 3.9%; 3.607 - 2.7%; 3.442 - 16.6%; 3.383 - 3.0%; 3.183 - 27.4%; 3.122 - 21.7%; 3.099 - 5.6%; 2.958 - 6.9%; 2.905 - 3.4%; 2.763 - 7.5%; 2.777 - 7.8%; 2,694 - 9.2%; 2.551 - 12.6%; 2.516 - 2.6%; 2.463 - 3.9%; 2.292 - 3.9%; 2.270 - 5.0%; 2.137 - 4.0%; 2.112 - 3.5%; 2.024 - 3.7%; 1,906 - 3.4%; 1.867 - 3.0%; 1.780 - 6.0%. 2. Способ получения кристаллической безводной δ-модификации N-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида по п. 1, характеризующейся тем, что растворяют N-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамид в органическом растворителе, выделяют кристаллиты из раствора методом замены растворителя или охлаждением с последующим фильтрованием, промыванием, замораживают кристаллиты и подвергают сублимационной сушке в течение 22-27 часов при конечной температуре на продукте не менее 25°C.2. A method for producing crystalline anhydrous δ-modification of N- (2-chloro-6-methylphenyl) -2 - [[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl-4-pyrimidinyl] amino ] -5-thiazolecarboxamide according to claim 1, characterized in that N- (2-chloro-6-methylphenyl) -2 - [[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl is dissolved -4-pyrimidinyl] amino] -5-thiazolecarboxamide in an organic solvent, crystallites are isolated from the solution by solvent replacement or cooling, followed by filtration, washing, crystallites are frozen and freeze-dried for 22-27 hours At a final product temperature of at least 25 ° C. 3. Способ по п. 2, характеризующийся тем, что для промывания используют дистиллированную воду.3. The method according to p. 2, characterized in that distilled water is used for washing. 4. Способ по п. 2 или 3, характеризующийся тем, что конечная температура при сублимационной сушке на продукте составляет 25°C-60°C.4. The method according to p. 2 or 3, characterized in that the final temperature during freeze-drying on the product is 25 ° C-60 ° C. 5. Применение кристаллической безводной δ-модификации N-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида по п. 1, обладающей ингибирующей активностью в отношении тирозинкиназ, для приготовления фармацевтической композиции для лечения иммунологических и онкологических заболеваний. 5. The use of crystalline anhydrous δ-modification of N- (2-chloro-6-methylphenyl) -2 - [[6- [4- (2-hydroxyethyl) -1-piperazinyl] -2-methyl-4-pyrimidinyl] amino] -5-thiazolecarboxamide according to claim 1, having an inhibitory activity against tyrosine kinases, for the preparation of a pharmaceutical composition for the treatment of immunological and oncological diseases.
RU2014116196/04A 2014-04-23 2014-04-23 Crystal anhydrous delta modification of n-(2-chlorine-6-methylphenyldiazomethane)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pirimidinyl]amino]-5-thiazolcarboxamide, method of its production and pharmaceutical composition based on it RU2567537C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2014116196/04A RU2567537C1 (en) 2014-04-23 2014-04-23 Crystal anhydrous delta modification of n-(2-chlorine-6-methylphenyldiazomethane)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pirimidinyl]amino]-5-thiazolcarboxamide, method of its production and pharmaceutical composition based on it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014116196/04A RU2567537C1 (en) 2014-04-23 2014-04-23 Crystal anhydrous delta modification of n-(2-chlorine-6-methylphenyldiazomethane)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pirimidinyl]amino]-5-thiazolcarboxamide, method of its production and pharmaceutical composition based on it

Publications (2)

Publication Number Publication Date
RU2014116196A true RU2014116196A (en) 2015-10-27
RU2567537C1 RU2567537C1 (en) 2015-11-10

Family

ID=54362649

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014116196/04A RU2567537C1 (en) 2014-04-23 2014-04-23 Crystal anhydrous delta modification of n-(2-chlorine-6-methylphenyldiazomethane)-2-[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pirimidinyl]amino]-5-thiazolcarboxamide, method of its production and pharmaceutical composition based on it

Country Status (1)

Country Link
RU (1) RU2567537C1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
CN101891738B (en) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 Dasatinib polymorph and preparation method and medical composition thereof

Also Published As

Publication number Publication date
RU2567537C1 (en) 2015-11-10

Similar Documents

Publication Publication Date Title
CU20200084A7 (en) SUBSTITUTE DERIVATIVES OF CARBOXAMIDE DIHYDROPIRAZOLO PIRAZINE
EA201800367A1 (en) METHODS OF TREATMENT OF HUNTINGTON'S DISEASE
BR112016028273A8 (en) radio-labeled derivatives of 2-amino6-fluoro-n- [5-fluoro-pyridin-3-yl] -pyrazol [1,5-a] pyrimidin3-carboxamide compound useful as atr kinase inhibitor, process for preparing said compound, as well as different solid forms thereof, use of these, and pharmaceutical composition
CU24411B1 (en) COMPOSITE DERIVED FROM BENZAMIDE REPLACED WITH 1,3-TIAZOL-2-ILO USEFUL FOR THE TREATMENT OF NEUROGENIC DISORDERS
EA201591614A1 (en) 1,3-OXAZIN-2-AMINE COMPOUNDS CONDENSED WITH PERFLUORATED CYCLOPROPYL AS BETA SECRETASE INHIBITORS AND METHODS OF THEIR APPLICATION
BR112012019050A2 (en) 8-fluoro-2- {methylamino) methyl] phenyl} -1,3,4,5-tetrahydro-6h-azepino [5,4,3cd] indo-6-one polymorphs.
HRP20070433A2 (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal
EA201790206A1 (en) NEW 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS
NO20090723L (en) Condensed heterocyclic derivatives and methods of use
AR082667A1 (en) 6-CICLOALQUIL-PIRAZOLOPIRIMIDINONAS FOR THE TREATMENT OF CNS DISORDERS
CU20160183A7 (en) SALTS OF N- (CYANOMETIL) CHLORHYDRATE -4- (2- (4-MORPHOLINOPHENYLAMINE) PYRIMIDIN-4-IL) BENZAMIDA
ECSP14001627A (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTE 5-FLUORO-1H-PYRAZOLOPYRIDINES
NZ738836A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
CO6680645A2 (en) Oxadiazole inhibitors of leukotriene production
EA201790207A1 (en) NEW SUBSTITUTED PYRIMIDINE COMPOUNDS
EA201691997A1 (en) 2,4-TIAZOLINIDON DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
EA201791367A1 (en) 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PIRROL-5-AMIN COMPOUNDS - BETA SECRETASE INHIBITORS
EA201790209A1 (en) NEW 2.5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS
EA201592277A1 (en) DERIVATIVES 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO [1,5-A] PYRAZINE AS BETA SECRETASE INHIBITORS
AU2016203385B2 (en) Physically modified sago starch
MA39688A (en) HETEROARYL COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC DISEASES
MX2016008536A (en) Fluoro-naphthyl derivatives.
EA201592278A1 (en) DERIVATIVES 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO [1,5-A] PYRAZIN-3 (2H) -ON AS BETA SECRETASE INHIBITORS (BACE)
BR112015014964A2 (en) new methysergide derivatives
BR112016023811B8 (en) MANUFACTURING METHOD FOR TRIAZINE, PYRIMIDINE AND PYRIDINE DERIVATIVES, THEIR INTERMEDIATES AND THEIR MANUFACTURING METHODS

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20180418

MF41 Cancelling an invention patent (total invalidation of the patent)

Effective date: 20190320